These studies indicate the presence of SMARCA2/SMARCA4 paralog dependency for the maintenance of ATPase activity of the SWI/SNF complex and represent a novel treatment strategy of targeting SMARCA2 in SMARCA4-mutant cancers and vice versa. The gene discussed is SMARCA1; the disease is cancer.